References

1. Nelson A. Combined oral contraceptives. In: Hatcher RA, Trussel J, Nelson AL, et al. Contraceptive Technology, 19th rev. ed. New York: Ardent Media, 2007:193-270.

2. Blackburn RD, Cunkelman A, Zlidar VM. Oral contraceptives—An update. Popul Rep A 2000;28:1-32.

3. Abma JC, Chandra A, Mosher WD, et al. Fertility, family planning, and women's health: New data from the 1995 National Survey of Family Growth. Vital Health Stat 1997;19:series 23.

4. Henshaw SK. Unintended pregnancy in the United States. Fam Plann Perspect 1998;30:24-29.

5. Cates W Jr, and the American Social Health Association Panel. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. Sex Transm Dis 1999;26:S2-S7.

6. Hatcher RA, Namnoum AB. The menstrual cycle. In: Hatcher RA, Trussel J, Nelson AL, et al. Contraceptive Technology, 19th rev. ed. New York: Ardent Media, 2007:7-18.

7. Trussel J. Choosing a contraceptive: Efficacy, safety, and personal considerations. In: Hatcher RA, Trussel J, Nelson AL, et al. Contraceptive Technology, 19th rev. ed. New York: Ardent Media, 2007:19-48.

8. Anonymous. Choice of contraceptives: Treatment Guidelines from The Medical Letter. Med Lett 2007;64:101-108.

9. Vessey MP, Painter R. Endometrial and ovarian cancer and oral contraceptives—Findings in a large cohort study. Br J Cancer 1995;71:1340-1342.

10. Ness RB, Grisso JA, Klapper J, et al., for the SHARE Study Group. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. Steroid hormones and reproduction. Am J Epidemiol 2000;152:233-241.

11. Burkman RT. Oral contraceptives: Current status. Clin Obstet Gynecol 2001;44:62-72.

12. Schildkraut JM, Calingaert B, Marchbanks PA, et al. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 2002;94:32-38.

13. Iyer V, Farquhar C, Jepson R. Oral contraceptive pills for heavy menstrual bleeding. Cochrane Database Syst Rev 2000;2: CD000154.

14. Panser LA, Phipps WR. Type of oral contraceptive in relation to acute, initial episodes of pelvic inflammatory disease. Contraception 1991;43:91-99.

15. Tanis BC, van den Bosch MA, Kemmeren JM, et al. Oral contraceptives and the risk of myocardial infarction. Arch Intern Med 2001;161:1065-1070.

16. Schwingl PJ, Ory HW, Visness CM. Estimates of the risk of cardiovascular death attributable to low-dose oral contraceptives in the United States. Am J Obstet Gynecol 1999;180:241-249.

17. Chang CL, Donaghy M, Poulter N. Migraine and stroke in young women: Case-control study. The World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. BMJ 1999;318:13-18.

18. Curtis KM, Chrisman CE, Peterson HB, WHO Programme for Mapping Best Practices in Reproductive Health. Contraception for women in selected circumstances. Obstet Gynecol 2002;99:1100-1112.

19. Petitti DB. Clinical practice. Combination estrogen-progestin oral contraceptives. N Engl J Med 2003;349:1443-1450.

20. Hennessy S, Berlin JA, Kinman JL, et al. Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: A meta-analysis and formal sensitivity analysis. Contraception 2001;64:125-133.

21. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: Meta-analysis. BMJ 2001;323:131-134.

22. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002;346:2025-2032.

23. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713-1727.

24. Redmond G, Godwin AJ, Olson W, Lippman JS. Use of placebo controls in an oral contraceptive trial: Methodological issues and adverse event incidence. Contraception 1999;60:81-85.

25. Graham CA, Ramos R, Bancroft J, et al. The effects of steroidal contraceptives on the well-being and sexuality of women: A double-blind, placebo-controlled, two-centre study of combined and progestogen-only methods. Contraception 1995;52:363-369.

26. Rosenberg MJ, Meyers A, Roy V. Efficacy, cycle control, and side effects of low-and lower-dose oral contraceptives: A randomized trial of 20 micrograms and 35 micrograms estrogen preparations. Contraception 1999;60:321-329.

27. Duramed Pharmaceuticals. Product information for Seasonale. Pomona, NY: Duramed Pharmaceuticals, Inc; 2003(Sep).

28. Vercellini P, Frontino G, De Giorgi O, et al. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril 2003;80: 560-563.

29. Berlex, Inc. Product information for Yasmin. Montville, NJ: Berlex, Inc; 2005(Feb).

30. Mircette Patient Information Guide. http://www.mircette.com/guide.html.

31. Bristol-Myers Squibb Co. Product information for Ovcon 35. Princeton, NJ: Bristol-Myers Squibb Co; 2003(Nov).

32. Wyeth Pharmaceuticals, Inc. Product information for levonorgestrel 90 mcg and ethinyl estradiol 20 mc (Lybrel). Philadelphia, PA: Wyeth Pharmaceuticals; 2007(May).

33. Tom W. Oral contraceptive drug interactions. Pharmacist's Letter/Prescriber's Letter 2005;21:210903.

34. Anonymous. Ortho Evra—A contraceptive patch. Med Lett Drugs Ther 2002;1122:8.

35. Anonymous. An update on Ortho Evra and the risk of thromboembolism. Pharmacist's Letter/Prescribers Letter 2005;21:211202.

36. Smallwood GH, Meador ML, Lenihan JP, et al. for the Ortho Evra/Evra 002 Study Group. Efficacy and safety of a transdermal contraceptive system. Obstet Gynecol 2001;98:799-805.

37. Dieben TO, Roumen FJ, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol 2002;100:585-593.

38. Westhoff C. Bone mineral density and DMPA. J Reprod Med 2002;47:795-799.

39. Pharmacia and Upjohn. Product information for Depo-subQ Provera 104. New York: Pharmacia and Upjohn; 2005(Mar).

40. Toh YC, Jain J, Rahnny MH, et al. Suppression of ovulation by a new subcutaneous depot medroxyprogesterone acetate (104 mg/0.65 mL) contraceptive formulation in Asian women. Clin Ther 2004;26:1845-1854.

41. Berlex, Inc. Product information for Mirena. Montville, NJ: Berlex; 2004(Sep).

42. FEI Products LLC. Product information for Paragard T 380A. N. Tonawanda, NY: FEI Products LLC; 2003(0ct).

43. Moench TR, Chipato T, Padian NS. Preventing disease by protecting the cervix: The unexplored promise of internal vaginal barrier devices. AIDS 2001;15:1595-1602.

44. Cates W Jr, Raymond EG. Vaginal barriers and spermicides. In: Hatcher RA, Trus-sel J, Nelson AL, et al. Contraceptive Technology, 19th rev. ed. New York: Ardent Media, 2007:317-336.

45. Warner L, Steiner MJ. Male condoms. In: Hatcher RA, Trussel J, Nelson AL, et al. Contraceptive Technology, 19th rev. ed. New York: Ardent Media, 2007:297-316.

46. Davis KR, Weller SC. The effectiveness of condoms in reducing heterosexual transmission of HIV. Fam Plann Perspect 1999;31:272-279.

47. Kuyoh MA, Toroitich-Ruto C, Grimes DA, et al. Sponge versus diaphragm for contraception: A Cochrane review. Contraception 2003;67:15-18.

48. Jennings VH, Arevalo M. Fertility awareness-based methods. In: Hatcher RA, Trussel J, Nelson, AL, et al. Contraceptive Technology, 19th rev. ed. New York: Ardent Media, 2007:343-360.

Blood Pressure Health

Blood Pressure Health

Your heart pumps blood throughout your body using a network of tubing called arteries and capillaries which return the blood back to your heart via your veins. Blood pressure is the force of the blood pushing against the walls of your arteries as your heart beats.Learn more...

Get My Free Ebook


Post a comment